CLEAR-III Day-180 Results Presented at International Stroke Conference

CLEAR-III was all the talk at this year's International Stroke Conference (ISC). We had a number of presentations and posters discussing the Day-180 results of this six-year international multicenter trial exploring the delivery of alteplase, a thrombolytic ("clot buster"), via the extraventricular drain in patients with intraventricular hemorrhage (IVH). Thank you to all the clinical site staff and patients that contributed to this trial. There is alway more research needed when dealing with such a serious condition, but the knowledge gained on this project has been invaluable and will shape the future direction of future research for years to come.

Interview with Dr. Daniel Hanley, Co-principal Investigator for CLEAR-III

Photos of the team attending ISC

ISC Media Release

Abstracts and Slides  Dr. Hanley's presentation was LB12. Dr. Issam Awad's presentation was LB13

 Additionally, there have been lots of new articles about the CLEAR III results:

Continue reading

CLEAR III Final Awards Ceremony


We will be hosting our CLEAR III Final Awards Ceremony on Thursday, January 21st

during our Monthly Webinar at 8 am and 2 pm.


If you are not already registered, please use the links below.


8am: https://attendee.gotowebinar.com/register/7483230323796250882 

2pm: https://attendee.gotowebinar.com/register/2814668767728319233 


CLEAR-III Closes Enrollment

The 500th and final patient in the CLEAR-III trial was randomized on 14-Jan-2015, closing the enrollment period for this trial. Sites have until the end of January to enter any remaining screens. The trial continues in follow-up with the last patient's last visit (LPLV) expected in February 2016. 


Neurocritical Care Society Meeting for 2014

Neurocritical Care Society Meeting for 2014

The 12th Annual Neurocritical Care Society (NCS) Meeting will be held this year in Seattle on 11-14 September. There will be a comprehensive session on intracerebral hemorrhage, including reviews of exciting recent advances in the translational, epidemiological and clinical areas. 

Friday’s focus on ICH will provide cutting-edge science, clarity in the practice of complex clinical problems, and maybe even stir up a little controversy. Our MISTIE/CLEAR Lead Investigator, Dr. Daniel F. Hanley, will be speaking as well, on interventional treatment so you don't want to miss it. Click here for details.


CLEAR-III Patient 400-NorthShore Long Island!!!


Google Visualization API Sample
Last updated: 16-Dec-2015
CLEAR-III Enrollment Graph
CLEAR 3 Enrollment Graph
Last Updated: 16-Jan-2015